Bio-Techne Corporation (TECH)

Market Cap	8.34B
Revenue (ttm)	1.22B
Net Income (ttm)	73.36M
Shares Out	155.55M
EPS (ttm)	0.46
PE Ratio	118.28
Forward PE	26.99
Dividend	$0.32 (0.59%)
Ex-Dividend Date	Aug 18, 2025

Volume	271,410
Open	54.05
Previous Close	54.41
Day's Range	53.38 - 54.19
52-Week Range	46.01 - 80.95
Beta	1.47
Analysts	Buy
Price Target	70.91 (+32.2%)
Earnings Date	Oct 29, 2025

About TECH

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue cultur...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 9, 1989
• Employees: 3,050
• Stock Exchange: NASDAQ
• Ticker Symbol: TECH
• Website: https://www.bio-techne.com

Financial Performance

In 2025, Bio-Techne's revenue was $1.22 billion, an increase of 5.23% compared to the previous year's $1.16 billion. Earnings were $73.36 million, a decrease of -56.35%.

Analyst Summary

According to 12 analysts, the average rating for TECH stock is "Buy." The 12-month stock price target is $70.91, which is an increase of 32.20% from the latest price.

Price Target

$70.91

(32.20% upside)

Analyst Consensus: Buy